Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
McKesson
Johnson and Johnson
Boehringer Ingelheim

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR GEODON


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Geodon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00141271 ↗ A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression Completed Pfizer Phase 3 2005-07-01 This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
NCT00141271 ↗ A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression Completed Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Phase 3 2005-07-01 This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Geodon

Condition Name

Condition Name for Geodon
Intervention Trials
Schizophrenia 17
Bipolar Disorder 15
Schizoaffective Disorder 7
Depression 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Geodon
Intervention Trials
Disease 17
Schizophrenia 17
Bipolar Disorder 16
Depression 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Geodon

Trials by Country

Trials by Country for Geodon
Location Trials
United States 181
India 14
Malaysia 5
Colombia 4
Russian Federation 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Geodon
Location Trials
New York 14
Massachusetts 13
California 12
Texas 11
Ohio 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Geodon

Clinical Trial Phase

Clinical Trial Phase for Geodon
Clinical Trial Phase Trials
Phase 4 15
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Geodon
Clinical Trial Phase Trials
Completed 38
Terminated 7
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Geodon

Sponsor Name

Sponsor Name for Geodon
Sponsor Trials
Pfizer 25
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 8
Massachusetts General Hospital 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Geodon
Sponsor Trials
Other 64
Industry 37
NIH 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
McKesson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.